Beta Bionics (NASDAQ:BBNX) Shares Gap Down on Analyst Downgrade

Beta Bionics, Inc. (NASDAQ:BBNX) gapped down prior to trading on Wednesday after Robert W. Baird lowered their price target on the stock from $28.00 to $14.00. The stock had previously closed at $13.97, but opened at $12.89. Robert W. Baird currently has a neutral rating on the stock. Beta Bionics shares last traded at $12.47, with a volume of 1,808,308 shares trading hands.

Several other brokerages have also recently issued reports on BBNX. Truist Financial dropped their price target on Beta Bionics from $37.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Lake Street Capital lifted their target price on Beta Bionics from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Piper Sandler reaffirmed an “overweight” rating and set a $32.00 price target (up from $26.00) on shares of Beta Bionics in a report on Wednesday, October 29th. Bank of America lowered shares of Beta Bionics from a “buy” rating to a “neutral” rating in a research report on Friday, January 9th. Finally, Wall Street Zen downgraded shares of Beta Bionics from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $23.33.

Insider Buying and Selling at Beta Bionics

In related news, insider Mike Mensinger sold 2,200 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $30.10, for a total value of $66,220.00. Following the completion of the sale, the insider owned 80,752 shares in the company, valued at $2,430,635.20. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Stephen Feider sold 20,000 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $29.53, for a total transaction of $590,600.00. Following the sale, the chief financial officer directly owned 42,614 shares in the company, valued at approximately $1,258,391.42. This represents a 31.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 32,490 shares of company stock worth $960,835 over the last 90 days.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Q4 & full‑year results showed strong top‑line growth and an earnings beat: Q4 net sales $32.1M (57% YoY), FY2025 sales $100.3M (up 54%), and EPS beat consensus (loss per share of $0.30 vs. estimate of $0.42). Management guided 2026 revenue to ~$130M–$135M, above consensus, and reported $264.7M in cash — fundamentals that support longer‑term growth expectations. Company Press Release
• Positive Sentiment: Commercial traction and product pipeline progress: installed base grew to ~35k users (up 129% YoY), PBP channel sales surged, and the company completed a first‑in‑human Phase 2a bihormonal feasibility trial — all supportive of sustained revenue expansion and pipeline value. QuiverQuant Summary
• Neutral Sentiment: Earnings call/transcripts and slide deck are available for investors to review details on channel mix, margins, and clinical plans — useful for modeling but not immediate catalysts. Earnings Call Transcript
• Neutral Sentiment: Some analysts are taking a cautious stance but not unanimous: TD Cowen maintained a Hold with a $16 target — a signal that the street is mixed on near‑term prescription/reimbursement headwinds vs. growth. TipRanks Note
• Negative Sentiment: Analyst downgrade/target cut: Robert W. Baird lowered its price target from $28 to $14 and moved to Neutral — a headline likely contributing to today’s sell‑side pressure and reduced upside in near term. The Fly: Baird Cuts Target
• Negative Sentiment: Investor litigation alerts from multiple law firms (Faruqi & Faruqi; Pomerantz) introduce headline risk and potential legal overhang that can pressure the stock and increase volatility. Faruqi & Faruqi Notice Pomerantz Alert
• Negative Sentiment: Profitability remains a concern: despite revenue growth, the company reported sizable operating losses and negative adjusted EBITDA — a reminder that revenue growth is not yet translating into GAAP profitability. Zacks Coverage

Hedge Funds Weigh In On Beta Bionics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. GPS Wealth Strategies Group LLC boosted its position in shares of Beta Bionics by 45.0% in the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock worth $29,000 after buying an additional 450 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Beta Bionics by 0.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 331,623 shares of the company’s stock worth $10,105,000 after acquiring an additional 931 shares during the last quarter. Deutsche Bank AG lifted its holdings in shares of Beta Bionics by 3.4% in the fourth quarter. Deutsche Bank AG now owns 39,300 shares of the company’s stock valued at $1,197,000 after purchasing an additional 1,296 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Beta Bionics by 203.6% in the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after purchasing an additional 1,594 shares during the last quarter. Finally, Summit Securities Group LLC purchased a new position in shares of Beta Bionics during the 4th quarter worth approximately $52,000.

Beta Bionics Trading Down 2.6%

The firm has a market capitalization of $599.25 million and a PE ratio of -6.98. The stock’s 50 day moving average price is $21.78 and its two-hundred day moving average price is $22.53.

Beta Bionics (NASDAQ:BBNX) last announced its earnings results on Tuesday, February 17th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.12. The firm had revenue of $32.12 million for the quarter. Beta Bionics had a negative return on equity of 20.02% and a negative net margin of 73.02%.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.